Ashling Wahner

In preliminary research, the targeted alpharadiotherapy agent 225Ac-FL-020 has demonstrated superior antitumor activity in xenograft models and a favorable safety profile.

In a recent interview, Sophia Rose O’Brien, M.D., shared her insights on the roles and limitations of FDG PET/CT and FES PET/CT in the imaging of patients with metastatic breast cancer.